TUG-770 Inhibitor

Name: TUG-770 Inhibitor; MyBioSource
Brand: MyBioSource
SKU: MBS5764493
Availability: InStock
Rating: 5 (10 reviews)

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5764493

TUG-770 is a highly potent agonist of free fatty acid receptor 1 (FFA1/GPR40, EC50: 6nM for hFFA1). More details

Please Inquire

Product Documentation

Sample Manual Insert View PDF

Testing Data View PDF

Certificate of Analysis (COA) View PDF

QC Report View PDF

Material Safety Data Sheet View PDF

Technical Datasheet View PDF

Protocol View PDF

Product Overview

Online Datasheet in PDF

Product Name

TUG-770, Inhibitor

Full Product Name

TUG-770

Product Gene Name

TUG-770, inhibitor

Form/Format

Solid. Powder

Purity/Purification

98.00%

Preparation and Storage

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

Molecular Weight

307.32

Solubility

DMSO: 100mg/mL (325.39mM)
Water: Insoluble
(<1mg/ml refers to the product slightly soluble or insoluble)

Formula

C19H14FNO2

SMILES

N#CCc(cccc1)c1C#Cc1cc(F)c(CCC(O)=O)cc1

CAS Number

1402601-82-4

In Vitro

Examination of TUG-770 in an acute intraperitoneal glucose tolerance test (IPGTT) in normal mice revealed a good dose-dependent response with maximal reduction in glucose level reached at 50mg/kg. The effect of TUG-770 was fully sustained after 29 days of daily oral treatment, Additional evaluation of TUG-770 in rats confirmed a significant glucose-lowering effect for the high doses already after 10 min and for all doses after 30 minutes.

Product Categories/Family for TUG-770, inhibitor

Endocrinology/Hormones; GPR

Product References and Citations for TUG-770, inhibitor

Christiansen E, Hansen SV, Urban C, Discovery of TUG-770: A Highly Potent Free Fatty Acid Receptor 1 (FFA1/GPR40) Agonist for treatment,of Type 2 Diabetes. ACS Med Chem Lett. 2013 May 9;4(5):441-445.
Christiansen E, Hansen SV, Urban C, Discovery of TUG-770: A Highly Potent Free Fatty Acid Receptor 1 (FFA1/GPR40) Agonist for treatment,of Type 2 Diabetes. ACS Med Chem Lett. 2013 May 9;4(5):441-445.
Urano Y, et al. Comparative hepatic transcriptome analyses revealed possible pathogenic mechanisms of fasiglifam (TAK-875)-induced acute liver injury in mice. Chem Biol Interact. 2018 Sep 20;296:185-197.
Urano Y, et al. Comparative hepatic transcriptome analyses revealed possible pathogenic mechanisms of fasiglifam (TAK-875)-induced acute liver injury in mice. Chem Biol Interact. 2018 Sep 20;296:185-197.

Other Notes

Small volumes of TUG-770, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for TUG-770 purchase

MBS5764493 is an inhibitor targeting TUG-770.